Douglas Fambrough - 10 Dec 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Chief Executive Officer, Director
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 10 Dec 2021
Net transactions value: +$599,987
Form type: 4
Filing time: 13 Dec 2021, 18:33:46 UTC
Previous filing: 10 Aug 2021
Next filing: 17 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$100,000	+33,670	+78%	$2.97	76,834	10 Dec 2021	Direct
transaction	DRNA	Common Stock	Options Exercise	$499,987	+146,195	+190%	$3.42	223,029	10 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-33,670	-15%	$0.000000	191,330	10 Dec 2021	Common Stock	33,670	$2.97	Direct	F1
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-146,195	-73%	$0.000000	55,055	10 Dec 2021	Common Stock	146,195	$3.42	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the transaction date, the option was fully vested. The option vested in 48 monthly installments over the four-year period starting on the last day of January 2017.
F2	As of the transaction date, the option was fully vested. The option vested 1/48 monthly on last day of each month with a vesting start date of 07/30/2013.